Long-time ARVO member, Roger Vogel, MD, passed away June 10, 2015, after his battle with brain cancer. He was 74 years old.
Dr. Vogel was an experienced clinical researcher who made significant contributions to ophthalmology and to the preservation of sight. At the time of his death, he was a partner at Point Guard Partners, LLC, part of a management team created to help ophthalmic pharmaceutical, medical device and drug delivery companies move products from concept through FDA approval and into the market. During his 32 years in the ophthalmic pharmaceutical industry, Dr. Vogel led the development of more than a dozen commonly used ophthalmic pharmaceutical products in the areas of glaucoma, infectious disease, ocular inflammation, allergy and retinal disease. He held senior executive positions and consulting posts with companies such as Merck Co and Inc., Insite Vision, Bausch and Lomb, ISTA, Cambridge Antibody Therapeutics, Genaera and Sirion Therapeutics.
Through a generous contribution by Point Guard Partners LLC, the ARVO Foundation for Eye Research established the Dr. Roger Vogel Award for Pharmaceutical Research. The annual award is given to an ARVO member whose research furthers the development of pharmaceutical treatments for ophthalmic diseases. "It made [Dr. Vogel] very proud to have the award named for him and to have his life's work recognized in this way," said Barry Butler, Dr. Vogel's partner at Point Guard, The first award was presented in 2014.
Dr. Vogel received his MB, BS, LRCP and MRCS from University College, London. He was a member of the Royal College of Ophthalmology and a fellow of the Faculty of Pharmaceutical Medicine, and is the author of more than 50 peer-reviewed publications.